Journal of Immunology Research / 2012 / Article / Fig 7

Clinical Study

Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

Figure 7

Comparison of the IFN-γ-negative and IL-4-positive (Th2) subset of CD4-positive T cells before and after treatment in the PR + SD group and PD group. There were significant differences of Th2 cells in the PR + SD and PD groups between before treatment and after treatment (PR + SD group: , PD group: by Wilcoxon’s signed rank sum test).